Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligo

European Journal of Cell Biology

Volumn 83, Issue 11-12, 2004, Pages 797-803

  Steitz, Julia ^a   Wenzel, Jörg ^a   Gaffal, Evelyn ^a   Tüting, Thomas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Immune tolerance; Melanocytes, CD8+T cells; TRP2; Vitiligo

Indexed keywords

CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN RECOGNITION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL STIMULATION; CYTOTOXIC T LYMPHOCYTE; EPIDERMIS; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; MELANOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PIGMENT DISORDER; PRIORITY JOURNAL; PROTEIN BINDING; SKIN INFLAMMATION; SYSTEMATIC REVIEW; VITILIGO;

EID: 12344268632     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1078/0171-9335-00423     Document Type: Article

References (52)

1. Alferink, J., Tafuri, A., Vestweber, D., Hallmann, R., Hämmerling, G. J., Arnold, B., 1998. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 282, 1338-1341.
2. Baharav, E., Merimski, O., Shoenfeld, Y., Zigelman, R.. 1996. Tyrosinase as an autoantigen in patients with vitiligo. Clin. Exp. Immunol. 105, 84-88.
3. Berd, D., Mastrangelo, M. J., Lattime, E., Sato, T., Maguire, H. C. Jr., 1996. Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol. Immunother. 42, 263-267.
4. Bloom, M. B., Perry-Lalley, D., Robbins, P. F., Li, Y., el-Gamil, M., Rosenberg, S. A., Yang, J. C., 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453-459.
5. Boon, T., Cerottini, J.-C., van den Eynde, B., van der Bruggen, P., van Pel, A., 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365.
6. Bowne, W. B., Srinivasan, R., Wolchok, J. D., Hawkins. W. G., Blachere, N. E., Dyall, R., Lewis, J. J., Houghton, A. N., 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190, 1717-1722.
7. Bronte, V., Apolloni, E., Ronca, R., Zamboni, P., Overwijk, W. W., Surman, D. R., Restifo, N. P., Zanovello, P., 2000. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 60, 253-258.
8. Castelli, C., Tarsini, P., Mazzocchi, A., Rini, F., Rivoltini, L., Ravagnani, F., Gallino, F., Belli, F., Parmiani, G., 1999. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens. J. Immunol. 162, 1739-1748.
9. Colella, T. A., Bullock, T. N., Russell, L. B., Mullins, D. W., Overwijk, W. W., Luckey, C. J., Pierce, R. A., Restifo, N. P., Engelhard, V. H., 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 3, 1221-1232.
10. Condon, C., Watkins, S. C., Celluzzi, C. M., Thompson, K., Falo, L. D., 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 2, 1122-1128.
11. Cui, J., Bystryn, J. C., 1995. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch. Dermatol. 131, 314-318.
12. Das, P. K., van den Wijngaard, R. M., Wankowicz-Kalinska, A., Le Poole, I. C., 2001. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol. 22, 130-136.
13. Dittmar, M., Kahaly, G. J., 2003. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. Clin. Endocrinol. Metab. 88, 2983-2992.
14. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Rosenberg, S. A., 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854.
15. Fishman, P., Merimski, O., Baharav, E., Shoenfeld, Y., 1997. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 79, 1461-1464.
16. Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G., Laus, R., 1997. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159, 3113-3117.
17. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., Nussenzweig, M. C., 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779.
18. Kemp, E. H., Waterman, E. A., Weetman, A. P., 2001. Immunological pathomechanisms in vitiligo. Expert Rev. Mol. Med. 23, 1-22.
19. Kemp, E. H., Gawkrodger, D. J., MacNeil, S., Watson, P. F., Weetman, A. P., 1997. Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radio-immunoassay. J. Invest. Dermatol. 109, 69-73.
20. Lane, C., Leitch, J., Tan, X., Hadjati, J., Bramson, J. L., Wan, Y., 2004. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 64, 1509-1514.
21. Lang, K. S., Caroli, C. C., Muhm, A., Wernet, D., Moris, A., Schittek, B., Knauss-Scherwitz, E., Stevanovic, S., Rammensee, H. G., Garbe, C., 2001. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART-1. J. Invest. Dermatol. 116, 891-897.
22. Le Gal, F. A., Avril, M. F., Bosq, J., Lefebvr, P., Deschemin, J. C., Andrieu, M., Dore, M. X., Guillet, J. G., 2004. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J. Invest. Dermatol. 117, 1464-1470.
23. Limmer, A., Sacher, T., Alferink, J., Kretschmar, M., Schonrich, G., Nichterlein, T., Arnold, B., Hammerling, G. J., 1998. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur. J. Immunol. 28, 2395-2406.
24. Loftus, D. J., Castelli, C., Clay, T. M., Squarcina, P., Marincola, F. M., Nishimura, M. I., Parmiani, G., Appella, E., Rivoltini, L., 1996. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184, 647-657.
25. Mamula, M. J., Lin, R. H., Janeway, C. A.Jr., Hardin, J. A., 1992. Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. J. Immunol. 149, 789-795.
26. Mandelcorn-Monson, R. L., Shear, N. H., Yau, E., Sambhara, S., Barber, B. H., Spaner, D., DeBenedette, M. A., 2003. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J. Invest. Dermatol. 121, 550-6.
27. Ogg, G. S., Dunbar, P. R., Romero, P., Chen, J. L., Cerundolo, V., 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188, 1203-1208.
28. Ongenae, K., Van Geel, N., Naeyaert, J. M., 2003. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16, 90-100.
29. Okamoto, T., Irie, R. F., Fujii, S., Huang, S. K., Nizze, A. J., Morton, D. L., Hoon, D. S., 1998. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J. Invest. Dermatol. 111, 1034-1039.
30. Overwijk, W. W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carroll, M. W., Moss, B., Rosenberg, S. A., Restifo, N. P., 1999. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA 96, 2982-2987.
31. Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., Restifo, N. P., 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580.
32. Palermo, B., Campanelli, R., Garbelli, S., Mantovani, S., Lantelme, E., Brazzelli, V., Ardigo, M., Borroni, G., Martinetti, M., Badulli, C., Necker, A., Giachino, C., 2001. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J. Invest. Dermatol. 117, 326-332.
33. Parkhurst, M. R., Fitzgerald, E. B., Southwood, S., Sette, A., Rosenberg, S. A., Kawakami, Y., 1998. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58, 4895-4901.
34. Rosenberg, S. A., 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175-182.
35. Rosenberg, S. A., White, D. E., 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19, 81-84.
36. Scheibenbogen, C., Hunstein, W., Keilholz, U., 1994. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur. J. Cancer 30A, 1209-1211.
37. Schreurs, M. W., Eggert, A. A., de Boer, A. J., Vissers, J. L., van Hall, T., Offringa, R., Figdor, C. G., Adema, G. J., 2000. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res. 60, 6995-7001.
38. Song, Y. H., Connor, E., Li, Y., Zorovich, B., Balducci, P., Maclaren, N., 1994. The role of tyrosinase in autoimmune vitiligo. Lancet 344, 1049-1052.
39. Steitz, J., Brück, J., Steinbrink, K., Enk, A., Knop, J., Tüting, T., 2000. Genetic immunization with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int. J. Cancer 86., 89-9.
40. Steitz, J., Brück, J., Knop, J., Tüting, T., 2001. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+T cell-dependent mechanism. Gene Ther. 8, 1255-1263.
41. Steitz, J., Brück, J., Gambotto, A., Knop, J., Tüting, T., 2002. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther. 9, 208-213.
42. Stoitzner, P., Pfaller, K., Stossel, H., Romani, N., 2002. A close-up view of migrating Langerhans cells in the skin. J. Invest. Dermatol. 118, 117-125.
43. Tsukamoto, K., Jackson, I. J., Urabe, K., Montague, P. M., Hearing, V. J., 1992. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 11, 519-526.
44. Tüting, T., 1999. The immunology of cutaneous DNA immunization. Curr. Opin. Mol. Ther. 1, 216-225.
45. Tüting, T., Storkus, W. J., Falo, L. D., 1998. DNA immunization targeting the skin: Molecular control of adaptive immunity. J. Invest. Dermatol. 111, 183-188.
46. Tüting, T., Gambotto, A., De Leo, A. B., Robbins, P. D., Lotze, M. T., Storkus, W. J., 1999a. Induction of tumor antigen-specific immunity using DNA immunization in mice. Cancer Gene Ther. 6, 73-80.
47. Tüting, T., Gambotto, A., Storkus, W. J., De Leo, A. B., 1999b. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: Studies with the model tumor antigen β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther. 6, 629-636.
48. Wang, R. F., Appella, E., Kawakami, Y., Kang, X., Rosenberg, S. A., 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184, 2207-2216.
49. Wang, R. F., Johnston, S. L., Southwood, S., Sette, A., Rosenberg, S. A., 1998. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol. 160, 890-897.
50. Wölfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyerzum Büschenfelde, K.-H., Boon, T., 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24, 759-764.
51. Yee, C., Thompson, J. A., Roche, P., Byrd, D. R., Lee, P. P., Piepkorn, M., Kenyon, K., Davis, M. M., Riddell, S. R., Greenberg, P. D., 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192, 1637-1644.
52. Yokoyama, K., Suzuki, H., Yasumoto, K., Tomita, Y., Shibahara, S., 1994. Molecular cloning and functional analysis of a cDNA coding for human DOPAchrome tautomerase/tyrosinase-related protein-2. Biochim. Biophys. Acta 1217, 317-321.